FluoGuide Management

Management criteria checks 2/4

FluoGuide's CEO is Morten Albrechtsen, appointed in Jan 2018, has a tenure of 7.83 years. directly owns 9.11% of the company’s shares, worth SEK58.41M. The average tenure of the management team and the board of directors is 4.3 years and 5.6 years respectively.

Key information

Morten Albrechtsen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.8yrs
CEO ownership	9.1%
Management average tenure	4.3yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

CEO

Morten Albrechtsen (61 yo)

7.8yrs

Tenure

Mr. Morten Albrechtsen, M.D., BBA, has been the CEO at Fluoguide A/s since 2018. He is the Co-founder and serves as the Chief Executive Officer at radiotherapy specialists Nanovi ApS. Mr. Albrechtsen Found...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Morten Albrechtsen	Chief Executive Officer	7.8yrs	no data	9.11% SEK 58.4m
Ole Larsen	Chief Financial Officer	2.8yrs	no data	no data
Donna Haire	Chief Operating Officer	no data	no data	no data
Andreas Kjaer	CSO, Head of Scientific Advisory Board & Director	no data	no data	13.01% SEK 83.4m
Grethe Rasmussen	Chief Development Officer	6.8yrs	no data	no data
Jens Ellrich	Chief Medical Officer	1yr	no data	no data
Dorthe Mejer	Vice President of Clinical Development	5.8yrs	no data	no data

4.3yrs

Average Tenure

61yo

Average Age

Experienced Management: FLUO's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andreas Kjaer	CSO, Head of Scientific Advisory Board & Director	7.8yrs	no data	13.01% SEK 83.4m
Mats Thoren	Vice Chairman of the Board	4.4yrs	no data	no data
Peter Eriksen	Independent Chairman	6.8yrs	no data	no data
Michael Engsig	Independent Director	2.7yrs	no data	no data

5.6yrs

Average Tenure

58yo

Average Age

Experienced Board: FLUO's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/20 18:31
End of Day Share Price	2025/11/20 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

FluoGuide A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Christian Binder	Redeye

FluoGuide Management

Management criteria checks 2/4

Key information

Recent management updates

FluoGuide A/S, Annual General Meeting, Mar 27, 2025

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

Fluoguide A/S Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

Recent updates

New minor risk - Shareholder dilution

FluoGuide A/S has filed a Follow-on Equity Offering.

FluoGuide A/S to Report Q2, 2026 Results on Aug 25, 2026

FluoGuide A/S to Report Fiscal Year 2025 Final Results on Feb 25, 2026

Health Check: How Prudently Does FluoGuide (STO:FLUO) Use Debt?

Forecast to breakeven in 2027

New major risk - Revenue and earnings growth

FluoGuide A/S Announces Inclusion of the First Patient in its Phase II Clinical Trial (CT-005) Investigating FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 27, 2025

Forecast breakeven date pushed back to 2027

Here's Why We're Watching FluoGuide's (STO:FLUO) Cash Burn Situation

FluoGuide A/S Receives Approval for Phase II Trial in Head and Neck Cancer

New minor risk - Share price stability

FluoGuide A/S to Report Q3, 2025 Results on Nov 27, 2025

FluoGuide A/S Announces Publication of Positive Phase II Clinical Data for FG001 in Patients with Head and Neck Cancer

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

FluoGuide A/S Submits Clinical Trial Application for Phase II Trial in Head and Neck Cancer

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S to Report Q1, 2023 Results on May 31, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

New 90-day low: kr.46.20

FluoGuide A/S Announces First Patient Enrolled in the Phase I/II Clinical Trial Testing FG001 in Patients with High Grade Glioma

FluoGuide Appoints Henrik Moltke as Chief Financial Officer, Effective December 2020

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources